文献速递妇科

晚期或复发性黏液性卵巢癌的二次肿瘤细胞减灭术联合腹腔热灌注化疗

Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer.
PubMed 文献 · Obstet Gynecol · 2023-04-05

两例晚期或复发性原发性黏液性卵巢癌患者接受二次肿瘤细胞减灭术联合腹腔热灌注化疗,术后未追加化疗,两例均获完全且持久缓解,分别在术后21个月和27个月无复发证据。作者认为二次肿瘤细胞减灭术联合腹腔热灌注化疗是复发性原发性黏液性卵巢癌的潜在治疗选择。

要点

  • 两例晚期或复发性原发性黏液性卵巢癌接受二次肿瘤细胞减灭术联合腹腔热灌注化疗。
  • 术后未追加化疗,两例均达完全且持久缓解。
  • 分别在联合治疗后21个月和27个月无复发证据。

核心结论

  • 二次肿瘤细胞减灭术联合腹腔热灌注化疗是复发性原发性黏液性卵巢癌女性的潜在治疗选择。

研究设计与样本

  • 病例报告,共两例晚期或复发性原发性黏液性卵巢癌患者。

主要发现

  • 两例患者接受二次肿瘤细胞减灭术联合腹腔热灌注化疗,术后未追加化疗。
  • 两例均达完全且持久缓解,分别在联合治疗后21个月和27个月无复发证据。

临床怎么用

  • 作者认为二次肿瘤细胞减灭术联合腹腔热灌注化疗是复发性原发性黏液性卵巢癌的潜在治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced or recurrent primary mucinous ovarian cancer is typically incurable and associated with short progression-free and overall survival when treated with standard chemotherapy. Novel approaches are desperately needed for women with this disease. CASES: Two patients with advanced or recurrent primary mucinous ovarian cancer were treated with secondary cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). No additional chemotherapy was administered postoperatively. Both patients achieved a complete and durable response, with no evidence of recurrence at 21 and 27 months, respectively, after CRS with HIPEC. CONCLUSION: Secondary CRS with HIPEC represents a potential therapeutic option for women with recurrent primary mucinous ovarian cancer.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Conley AB, Fournier KF, Sood AK, et al. Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer. Obstet Gynecol. 2023. PMID: 37023452. doi:10.1097/AOG.0000000000005154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。